Conbercept
As of the edition of 20 October 2026, Conbercept is a protein: marketed, first approved in 2013 (CN); acts on PGF, VEGFA and VEGFB and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Protein
- First approved
- 27 November 2013 (CN)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Chengdu Kanghong Biotech
- Registered trials
- 33, 3 stopped early
- Disease areas
- Eye; Heart and blood vessels; Cancer; Hormones; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Conbercept.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 1 | 2 | 0 |
| Phase 1 | 4 | 1 | 0 | 0 |
| Phase 2 | 9 | 3 | 0 | 0 |
| Phase 3 | 7 | 2 | 0 | 3 |
| Phase 4 | 6 | 2 | 1 | 0 |
| All trials | 33 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Chengdu Kanghong Biotech | Originator and Lead sponsor of trials | 2009 to now |